Biotech Stocks Reviews
- Impact of Delta Variant Being Overanalyzed
Thu, Jul 22
The Covid delta variant is making waves, and several countries are voicing concern. Below we look at the · more » - FDA Places Magenta’s ADC Conditioning Program On Hold
Wed, Jul 21
Magentaannouncedthat the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning · more » - Eloxx To Present CF Data in Early Q4 2021
Thu, Jul 8
Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided anenrolmentupdate for ELX-02 · more » - Genentech Discontinues Affimed’s BCMA Candidate
Thu, Jul 1
Affimed had the Q1 businessupdate callthis morning. The call was not well received after the company did · more » - Jounce R&D Day 2021 Focuses on LILRB Family
Wed, Jun 30
Last week, Jounce hosted their RD day to update investors on their pipeline and future prospects (watch · more » - Eloxx Risk-Reward Compelling Ahead of Cystic Fibrosis Data
Mon, Jun 21
Eloxx (ELOX) is developing a cystic fibrosis treatment for the 12% of patients that Vertex’s therapies · more » - Jounce Hands Over CCR8 Clinical Development To Gilead
Thu, Jun 17
Earlier this week Jounce (JNCE)receiveda $25M milestone payment from Gilead (GILD) for advancing their · more » - US Phase 3 Study Validates Novavax Vaccine. All Eyes on Regulatory & Manufacturing
Mon, Jun 14
Novavax (NVAX)reportedPhase 3 from their US/Mexico trial and the data confirmed their vaccine as best in · more » - Implications of Aducanumab’s FDA Approval
Mon, Jun 7
The biotech market (XBI) is up over 4% today on news that the FDA approved Biogen’s aducanumab for · more »